CR20110380A - Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266) - Google Patents

Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)

Info

Publication number
CR20110380A
CR20110380A CR20110380A CR20110380A CR20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A
Authority
CR
Costa Rica
Prior art keywords
treatment
divisional
exp
cellular growth
abnormal cellular
Prior art date
Application number
CR20110380A
Other languages
English (en)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR20110380A publication Critical patent/CR20110380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula I en la que R2- R4 son como se han definido en esta memoria. Tales nuevos derivados de pirimidina son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en los mamíferos. Esta invención se refiere también a un método de uso de tales compuestos en el tratamiento del crecimiento celular anormal en los mamíferos especialmente en los seres humanos, y a composiciones farmacéuticas que contienen tales compuestos.
CR20110380A 2002-12-20 2011-07-06 Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266) CR20110380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43567002P 2002-12-20 2002-12-20
US50074203P 2003-09-05 2003-09-05

Publications (1)

Publication Number Publication Date
CR20110380A true CR20110380A (es) 2011-08-08

Family

ID=32685406

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8266A CR8266A (es) 2002-12-20 2006-03-02 Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR20110380A CR20110380A (es) 2002-12-20 2011-07-06 Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR8266A CR8266A (es) 2002-12-20 2006-03-02 Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Country Status (31)

Country Link
US (4) US7109335B2 (es)
EP (1) EP1625121B1 (es)
AP (1) AP2385A (es)
AR (1) AR043682A1 (es)
AT (1) ATE458731T1 (es)
AU (2) AU2003285614B2 (es)
CA (1) CA2529611C (es)
CR (2) CR8266A (es)
CY (1) CY1110069T1 (es)
DE (1) DE60331479D1 (es)
DK (1) DK1625121T3 (es)
DO (1) DOP2003000793A (es)
EA (1) EA013248B1 (es)
EC (1) ECSP066406A (es)
ES (1) ES2338545T3 (es)
GE (1) GEP20084357B (es)
IL (1) IL172047A (es)
MX (1) MXPA06002608A (es)
MY (1) MY142109A (es)
NL (1) NL1025067C2 (es)
NZ (1) NZ543719A (es)
OA (1) OA13309A (es)
PA (1) PA8593001A1 (es)
PE (1) PE20041016A1 (es)
PL (1) PL379330A1 (es)
PT (1) PT1625121E (es)
RS (1) RS20060097A (es)
SI (1) SI1625121T1 (es)
TN (1) TNSN06074A1 (es)
TW (1) TWI283673B (es)
WO (1) WO2004056807A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338545T3 (es) 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP4099212B2 (ja) * 2004-05-14 2008-06-11 ファイザー・プロダクツ・インク 異常な細胞増殖を処置するためのピリミジン誘導体
EP1756090A1 (en) * 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
JP4812763B2 (ja) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
CA2571482A1 (en) * 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Pyk2 inhibitors for stimulation of osteoblast function
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP1945631B8 (en) * 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
ATE497496T1 (de) * 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
DE102007010801A1 (de) * 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
AU2008229483A1 (en) * 2007-03-16 2008-09-25 University Of Florida Research Foundation, Inc. Kinase protein binding inhibitors
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
NZ582485A (en) 2007-07-17 2012-05-25 Rigel Pharmaceuticals Inc Cyclic amine substituted pyrimidinediamines as pkc inhibitors
CL2009000600A1 (es) * 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
CA2850594C (en) * 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
TW202304434A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 一種高活性的ｈｐｋ１激酶抑制劑

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
DE4131184A1 (de) 1991-09-19 1993-03-25 Bayer Ag Wasserbasierte, loesungsmittel- und emulgatorfreie mikrobizide wirkstoffkombination
AU2954992A (en) 1991-11-13 1993-06-15 Mta Kozponti Kemiai Kutato Intezete Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process
DE4137291A1 (de) 1991-11-13 1993-05-19 Bayer Ag Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2149815T3 (es) 1992-05-22 2000-11-16 Du Pont Imidazolinonas fungicidas.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
CA2233003A1 (en) 1995-10-02 1997-04-10 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c-receptor antagonists
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
PL331602A1 (en) 1996-08-06 1999-08-02 Pfizer Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
YU11299A (sh) 1996-09-04 2001-07-10 Pfizer Inc. Derivati indazola
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
DE19701931C1 (de) * 1997-01-21 1998-05-28 Siemens Ag Verfahren zur Detektion von Synchronizität zwischen mehreren digitalen Meßreihen mit Hilfe eines Rechners
WO1998037079A1 (en) 1997-02-19 1998-08-27 Berlex Laboratories, Inc. N-heterocyclic derivatives as nos inhibitors
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CN1144786C (zh) 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0109165A (pt) 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US7160896B2 (en) 2000-07-07 2007-01-09 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
ES2317923T3 (es) 2000-08-09 2009-05-01 Astrazeneca Ab Compuestos de cinolina.
EP1311500A2 (en) 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
BR0113358A (pt) 2000-08-21 2003-07-01 Astrazeneca Ab Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
HU230574B1 (hu) 2000-12-21 2023-11-28 Novartis Ag Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
JP4291135B2 (ja) * 2001-05-29 2009-07-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003032997A1 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1472213B1 (en) 2002-02-05 2010-06-09 Wyeth a Corporation of the State of Delaware Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
DE10205336A1 (de) 2002-02-07 2003-08-21 Bdd Group Holding Ag Zug Deuterierte Biphenylderivate
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ES2338545T3 (es) 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006522012A (ja) 2002-12-20 2006-09-28 アラキス リミテッド ベンゾキサゾシンおよびそのモノアミン再吸収阻害剤としての用途
BRPI0414059B8 (pt) * 2003-09-05 2021-05-25 Pfizer Prod Inc síntese seletiva de pirimidinas substituídas em cf3
EP1756090A1 (en) * 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
US7674796B2 (en) 2010-03-09
US20080300234A1 (en) 2008-12-04
AU2009208172B2 (en) 2011-06-16
NL1025067A1 (nl) 2004-06-22
NL1025067C2 (nl) 2005-02-15
OA13309A (en) 2007-04-13
PL379330A1 (pl) 2006-08-21
US7741336B2 (en) 2010-06-22
EA013248B1 (ru) 2010-04-30
AR043682A1 (es) 2005-08-10
PE20041016A1 (es) 2004-12-30
US7351712B2 (en) 2008-04-01
ES2338545T3 (es) 2010-05-10
ATE458731T1 (de) 2010-03-15
DE60331479D1 (de) 2010-04-08
AU2003285614B2 (en) 2009-05-14
AP2005003438A0 (en) 2005-12-31
TW200426148A (en) 2004-12-01
CA2529611C (en) 2009-12-15
MY142109A (en) 2010-09-15
PT1625121E (pt) 2010-03-11
IL172047A0 (en) 2009-02-11
AU2009208172A1 (en) 2009-09-10
EP1625121A1 (en) 2006-02-15
DK1625121T3 (da) 2010-05-10
MXPA06002608A (es) 2007-01-23
US20080182840A1 (en) 2008-07-31
SI1625121T1 (sl) 2010-04-30
IL172047A (en) 2012-04-30
AP2385A (en) 2012-03-23
TNSN06074A1 (en) 2007-10-03
EA200600122A1 (ru) 2006-06-30
AU2003285614A1 (en) 2004-07-14
GEP20084357B (en) 2008-04-29
ECSP066406A (es) 2006-09-18
CY1110069T1 (el) 2015-01-14
RS20060097A (en) 2008-11-28
TWI283673B (en) 2007-07-11
PA8593001A1 (es) 2005-02-04
US7109335B2 (en) 2006-09-19
US20050009853A1 (en) 2005-01-13
DOP2003000793A (es) 2011-07-31
NZ543719A (en) 2007-01-26
EP1625121B1 (en) 2010-02-24
CR8266A (es) 2007-01-18
US20060281774A1 (en) 2006-12-14
WO2004056807A1 (en) 2004-07-08
CA2529611A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
CR20110380A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
UY28894A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
ECSP088563A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY28150A1 (es) Agentes terapeuticos
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ECSP045146A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
UY28695A1 (es) Derivados de difenilazetidona
SV2006002089A (es) Nuevos imidazoles ref. docket 18699 (pc26195a)
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
PA8589801A1 (es) Aminoalcoxiindoles
UY28136A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
NI200500205A (es) "derivados de pirimidina para el tratamiento del crecimiento celular anorma."
AR036110A1 (es) Eurotinona y derivados de la misma, procedimiento para su preparacion, un microorganismo, composiciones farmaceuticas, procedimiento para su produccion, el uso de dichos derivados y composiciones para la preparacion de medicamentos, y uso de dicho microorganismo
CL2004000744A1 (es) Metodo para preparar derivados de fenilaminoquinazolinas; compuesto intermediario; y su metodo de preparacion.
AR033457A1 (es) Compuesto de piperazina, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para prepararlo
AR036680A1 (es) Procedimiento para preparar derivados de heterocicloalquilsulfonilpirazol y compuestos utiles en su preparacion
UY27576A1 (es) Moléculas pequenas para el tratamiento del crecimiento celular anormal
DOP2003000786A (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal.
DOP2005000086A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
UY28131A1 (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)